newsfilter
← Earnings
Earnings Releases·

Equillium — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $4.6 million ($0.04 per share) in Q3 2026 from $4.2 million ($0.06 per share) in Q3 2025, driven by a $1.3 million increase in R&D expenses offset by a $0.7 million decrease in G&A expenses.
  • Cash and cash equivalents rose to $53.3 million as of September 30, 2026, with a pro forma balance of $72.0 million following a $20 million financing tranche closed in October 2026, extending the cash runway into 2029.
  • Initiated the first-in-human Phase 1 trial for EQ504 in Australia in October 2026, with proof-of-mechanism data expected in Q2 2027 and a potential placebo-controlled proof-of-concept study in ulcerative colitis planned for the second half of 2027.
  • Management highlighted the differentiated multi-modal immunoregulatory mechanism of EQ504 and expressed confidence in the company's financial position to fund operations and advance the therapy to patients.
Company
EQUILLIUM INC
Sector
Healthcare
Industry
Biotechnology